VANCOUVER, BC / ACCESSWIRE / July 5, 2019 / HemaGenetics Technologies Corp. (the “Company” or “HTC”) is pleased to announce the appointment of Richard Paolone as a director of HTC effective immediately.
Bio of appointee
Richard Paolone – holds a Juris Doctorate and Bachelor of Arts degree. Mr. Paolone is currently employed at a boutique securities law firm that is focused on corporate finance and M&A in Toronto, Ontario. He has experience in the industries of natural resources, technology and cannabis. Mr. Paolone assists with corporate and debt restructuring by rehabilitating companies to enhance shareholder value. Mr. Paolone`s current positions include: director of Red Pine Petroleum Ltd. (RPN: TSXV) as of May 2019 – a company involved in oil and gas exploration and development and serves as Chief Executive Officer and Director of Rotonda Ventures Corp. as of February 2019 – a company involved in oil and gas, specifically frack water remediation. Mr. Paolone also serves as director and officer of other privately held Canadian companies in cannabis and mineral exploration.
HemaGenetics Technologies Corp.
On behalf of the Board of Directors
Ron Ozols, V.P. Communications
Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of HGT. Forward-looking information is based on certain key expectations and assumptions made by the management of HGT. Although HGT believes that the expectations and assumptions on which such forward-looking information is based on are reasonable, undue reliance should not be placed on the forward-looking information because HGT can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. HGT disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
SOURCE: HemaGenetics Technologies Corp.
View source version on accesswire.com: